VCM
SAGE icon

Versant Capital Management’s Sage Therapeutics SAGE Stock Holding History

Versant Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-505
Closed -$4.61K – 2709
2025
Q2 		$4.61K Sell
505
-980
-66% -$7.21K ﹤0.01% 2181
2025
Q1 		$11.8K Buy
1,485
+1,249
+529% +$9.14K ﹤0.01% 1640
2024
Q4 		$1.28K Sell
236
-110
-32% -$672 ﹤0.01% 2145
2024
Q3 		$2.5K Buy
346
+259
+298% +$2.37K ﹤0.01% 1509
2024
Q2 		$945 Buy
87
+57
+190% +$730 ﹤0.01% 1687
2024
Q1 		$562 Hold
30
– – ﹤0.01% 1670
2023
Q4 		$650 Buy
30
+22
+275% +$436 ﹤0.01% 1620
2023
Q3 		$165 Sell
8
-7
-47% -$202 ﹤0.01% 1894
2023
Q2 		$705 Buy
+15
New +$746 ﹤0.01% 1727

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Huntington National Bank
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Versant Capital Management's SAGE Position: Q3 2025 in Review

Versant Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 505 shares — an estimated $4.61K sold.

Versant Capital Management first reported a position in SAGE in Q2 2023 and held it in 9 quarters. The position peaked at $11.8K in Q1 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Versant Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Versant Capital Management sold 505 Sage Therapeutics shares in Q3 2025, an estimated $4.61K.
  • Versant Capital Management first reported a position in Sage Therapeutics in Q2 2023 and held it in 9 quarters.
  • Versant Capital Management's Sage Therapeutics position peaked at $11.8K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Versant Capital Management's 13F filing for Q3 2025, filed 27 Oct 2025.